Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
Why the study?
Does mavacamten reduce the fraction of patients meeting guideline criteria for septal reduction therapy in adults with symptomatic obstructive hypertrophic cardiomyopathy?
Population
Adults with symptomatic obstructive HCM eligible for septal reduction therapy
Comparison
Mavacamten evaluation
Follow-up
16 weeks
Authors
Discussion
Loading...
Member takes
Implication
May reduce SRT eligibility in symptomatic oHCM; extends low-certainty evidence with RCT data.
Structured PICO
Does mavacamten reduce the fraction of patients meeting guideline criteria for septal reduction therapy in adults with symptomatic obstructive hypertrophic cardiomyopathy?
P
Population
Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) with intractable symptoms who are eligible for septal reduction therapy (SRT)
I
Intervention
Mavacamten
O
Outcome
Fraction of patients meeting guideline criteria for SRT after 16 weeks
Mavacamten significantly reduces the proportion of patients meeting criteria for septal reduction therapy at 16 weeks in adults with highly symptomatic obstructive hypertrophic cardiomyopathy.
Limitations
- Long-term freedom from SRT remains to be determined
Cite This Study
Desai et al. (2022) studied this question.